Insulin degludec/insulin aspart

Insulin degludec/insulin aspart
Combination of
Insulin degludecLong-acting human insulin analog
Insulin aspartFast-acting human insulin analog
Clinical data
Trade namesRyzodeg
AHFS/Drugs.comProfessional Drug Facts
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[6][7][8][9] It contains insulin degludec and insulin aspart.[6] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[6]

The most frequently reported side effect is hypoglycemia (low blood glucose levels).[6]

It was approved for medical use in the European Union in January 2013,[6] and in Australia in November 2017.[2]

Medical uses

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[6]

Insulin degludec and insulin aspart are slightly different from human insulin.[6] The differences mean that insulin degludec is absorbed more slowly by the body.[6] This means it has a long duration of action.[6] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[6]

References

  1. ^ "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
  2. ^ a b c "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
  3. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  4. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  5. ^ Australian Public Assessment Report for insulin degludec (rys)/insulin aspart (rys) (PDF) (Report). Therapeutic Goods Administration (TGA).
  6. ^ a b c d e f g h i j k "Ryzodeg EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, et al. (July 2018). "Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)". Advances in Therapy. 35 (7): 928–936. doi:10.1007/s12325-018-0712-2. PMC 11343968. PMID 29796928. S2CID 85473292.
  8. ^ Mehta R, Chen R, Hirose T, John M, Kok A, Lehmann R, et al. (November 2020). "Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines". Diabetes, Obesity & Metabolism. 22 (11): 1961–1975. doi:10.1111/dom.14128. PMC 7689716. PMID 32618405.
  9. ^ Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D (2021). "Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns". Frontiers in Endocrinology. 12: 616514. doi:10.3389/fendo.2021.616514. PMC 7996092. PMID 33776914.


Stub icon

This article about an endocrine, nutritional, or metabolic disease is a stub. You can help Wikipedia by expanding it.